| 2024 |
1715: Inhibition of JAK3 |
1716: STAT5 inhibition |
Jan 5, 2020 |
Nov 3, 2021 |
1 AOP
|
| 1969 |
1672: Inhibition of LS function. |
1673: Alveolar collapse |
Jul 3, 2019 |
Jul 3, 2019 |
1 AOP
|
| 2255 |
1672: Inhibition of LS function. |
1498: Loss of alveolar capillary membrane integrity |
Jan 8, 2021 |
Jan 8, 2021 |
None
|
| 2256 |
1672: Inhibition of LS function. |
1677: Reduced tidal volume |
Jan 8, 2021 |
Jan 8, 2021 |
None
|
| 2370 |
1672: Inhibition of LS function. |
1250: Decreased lung function |
Apr 27, 2021 |
Apr 27, 2021 |
1 AOP
|
| 1637 |
1463: Inhibition of lysyl oxidase |
1464: Reduction of collagen crosslinking |
Aug 3, 2017 |
Aug 3, 2017 |
1 AOP
|
| 1951 |
1658: Methionine synthase |
1661: Homocysteine increases |
Jun 14, 2019 |
Jun 14, 2019 |
None
|
| 1950 |
1659: MTHFR inhibition |
1661: Homocysteine increases |
Jun 14, 2019 |
Jun 14, 2019 |
None
|
| 1673 |
1481: Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) |
1482: Depletion, mtDNA |
Oct 25, 2017 |
Oct 25, 2017 |
1 AOP
|
| 1864 |
1604: Inhibition of N-linked glycosylation |
1605: Accumulation, misfolded proteins |
Mar 6, 2019 |
Mar 6, 2019 |
1 AOP
|
| 1569 |
1429: Inhibition of Ca Channels |
1430: Inhibition of neurotransmitter release |
Jun 23, 2017 |
Jun 23, 2017 |
2 AOPs
|
| 3422 |
2286: Na⁺/K⁺-ATPase |
1535: Heart failure |
Nov 21, 2024 |
Nov 21, 2024 |
None
|
| 3423 |
2286: Na⁺/K⁺-ATPase |
1321: Increased, intracellular sodium (Na+) |
Nov 21, 2024 |
Nov 21, 2024 |
None
|
| 1570 |
1430: Inhibition of neurotransmitter release |
1428: Analgesia |
Jun 23, 2017 |
Jun 23, 2017 |
1 AOP
|
| 1573 |
1430: Inhibition of neurotransmitter release |
1432: Anti-depressant Activity |
Jun 23, 2017 |
Jun 23, 2017 |
1 AOP
|
| 3536 |
2311: PI3K-Akt pathway |
1115: Increase, ROS |
May 22, 2025 |
May 22, 2025 |
1 AOP
|
| 2403 |
1885: Inhibition of Plxna2 |
1886: Overexpression of rasl11b |
May 28, 2021 |
Dec 12, 2021 |
1 AOP
|
| 2851 |
2100: Inhibition of rapid delayed rectifying potassium current |
1961: Prolongation of Action Potential |
Jan 29, 2023 |
Jan 29, 2023 |
1 AOP
|
| 2974 |
2155: SULT1E1 inhibition |
1973: Increased, estrogens |
Jul 28, 2023 |
Jul 28, 2023 |
None
|
| 3390 |
2155: SULT1E1 inhibition |
2251: Increased E2 availability |
Nov 15, 2024 |
Feb 21, 2025 |
1 AOP
|
| 1891 |
1627: tyrosinase |
1628: Reduction of L-Dopaquinone |
May 3, 2019 |
May 3, 2019 |
1 AOP
|
| 3016 |
2174: Inhibition VEGF/VEGFR pathway |
2161: Increase, Vascular disrupting effects |
Aug 21, 2023 |
Aug 21, 2023 |
None
|
| 3025 |
2174: Inhibition VEGF/VEGFR pathway |
1928: increased，Vascular endothelial dysfunction |
Aug 21, 2023 |
Aug 21, 2023 |
1 AOP
|
| 775 |
766: Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme |
775: Increased, Plasma tyrosine |
Nov 29, 2016 |
Dec 3, 2016 |
1 AOP
|
| 635 |
619: Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) |
620: Increased, serotonin (5-HT) 1 |
Nov 29, 2016 |
Dec 3, 2016 |
None
|